Masimo Co. (NASDAQ:MASI) Receives Average Rating of “Moderate Buy” from Brokerages

Masimo Co. (NASDAQ:MASI) has been given a consensus rating of “Moderate Buy” by the seven analysts that are covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $144.29.

Several research analysts have recently weighed in on MASI shares. Piper Sandler boosted their price objective on shares of Masimo from $160.00 to $165.00 and gave the stock an “overweight” rating in a research note on Wednesday. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a report on Wednesday. Finally, Stifel Nicolaus upgraded Masimo from a “hold” rating to a “buy” rating and upped their price objective for the company from $148.00 to $170.00 in a research note on Monday, April 15th.

Masimo Price Performance

Shares of MASI opened at $127.94 on Friday. The company has a quick ratio of 1.31, a current ratio of 2.31 and a debt-to-equity ratio of 0.62. Masimo has a twelve month low of $75.22 and a twelve month high of $153.93. The stock has a market capitalization of $6.80 billion, a P/E ratio of 87.03 and a beta of 0.97. The company has a 50 day moving average of $118.78 and a 200-day moving average of $127.81.

Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.09. Masimo had a net margin of 4.01% and a return on equity of 13.26%. The company had revenue of $496.30 million during the quarter, compared to the consensus estimate of $493.92 million. During the same period in the prior year, the business posted $0.62 EPS. The company’s quarterly revenue was up 9.0% on a year-over-year basis. As a group, equities research analysts forecast that Masimo will post 3.63 EPS for the current fiscal year.

Institutional Investors Weigh In On Masimo

A number of institutional investors have recently made changes to their positions in the company. Riverview Trust Co bought a new position in shares of Masimo during the first quarter worth approximately $25,000. Byrne Asset Management LLC acquired a new position in Masimo in the 4th quarter valued at $28,000. GAMMA Investing LLC increased its position in Masimo by 75.0% during the 2nd quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock worth $33,000 after buying an additional 111 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in shares of Masimo by 851.6% during the fourth quarter. EverSource Wealth Advisors LLC now owns 295 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 264 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of Masimo during the fourth quarter worth $36,000. Institutional investors own 85.96% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.